At F-star we are dedicated to transforming the lives of patients with cancer through the development of novel, innovative tetravalent bispecific antibodies.
We believe our technology will overcome many of the challenges facing current immuno-oncology therapies, because of the strong dual immune activation enabled by tetravalent bispecific binding.
We believe our tetravalent (mAb2) bispecifics have the following advantages:
- Naturalhuman antibody, meaning easier manufacturing with a favorable clinical safety profile
- Targeted enhanced bispecific activity through four binding sites
- Receptor clustering to drive stronger biological potency than other bispecific approaches
We have used this technology to generate a pipeline of bispecifics designed to safely reactivate the immune system in order to target hard-to-treat cancers.